Datos del Documento

Por favor, use este identificador para citar o enlazar este documento: https://ria.asturias.es/RIA/handle/123456789/12570
Título : Epigenetics in cancer therapy and nanomedicine
Autor : Roberti, Annalisa
Valdés, Adolfo F
Torrecillas, Ramón
Fraga, Mario F
Fernández, Agustín F
Palabras clave : Epigenetics
HDCA inhibitors
DNMT inhibitors
Fecha de publicación : 16-may-2019
Editorial : BMC
Citación : Roberti A, Valdes AF, Torrecillas R, Fraga MF, Fernandez AF. Epigenetics in cancer therapy and nanomedicine. Clin Epigenetics. 2019 May 16;11:81. doi: 10.1186/s13148-019-0675-4. PMID: 31097014
Resumen : The emergence of nanotechnology applied to medicine has revolutionized the treatment of human cancer. As in the case of classic drugs for the treatment of cancer, epigenetic drugs have evolved in terms of their specificity and efficiency, especially because of the possibility of using more effective transport and delivery systems. The use of nanoparticles (NPs) in oncology management offers promising advantages in terms of the efficacy of cancer treatments, but it is still unclear how these NPs may be affecting the epigenome such that safe routine use is ensured. In this work, we summarize the importance of the epigenetic alterations identified in human cancer, which have led to the appearance of biomarkers or epigenetic drugs in precision medicine, and we describe the transport and release systems of the epigenetic drugs that have been developed to date.
URI : https://ria.asturias.es/RIA/handle/123456789/12570
ISSN : 1868-7075
Aparece en las colecciones: Open Access DRIVERset

Archivos en este documento:
Fichero Tamaño Formato  
Archivo.pdf1.8 MBAdobe PDFVer/Abrir
Mostrar el registro Completo

Ver estadísticas del documento

Este documento está sujeto a una licencia Creative Commons: Licencia Creative Commons Creative Commons